SPF Beheer BV continued to hold its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 432,986 shares of the medical research company’s stock at the end of the second quarter. Thermo Fisher Scientific comprises 3.5% of SPF Beheer BV’s portfolio, making the stock its 3rd largest position. SPF Beheer BV owned about 0.11% of Thermo Fisher Scientific worth $75,543,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Ledyard National Bank raised its position in Thermo Fisher Scientific by 152.8% in the first quarter. Ledyard National Bank now owns 1,795 shares of the medical research company’s stock valued at $276,000 after buying an additional 1,085 shares during the period. Boys Arnold & Co. Inc. raised its position in Thermo Fisher Scientific by 62.9% in the first quarter. Boys Arnold & Co. Inc. now owns 4,889 shares of the medical research company’s stock valued at $751,000 after buying an additional 1,888 shares during the period. Rockland Trust Co. raised its position in Thermo Fisher Scientific by 1.8% in the first quarter. Rockland Trust Co. now owns 27,079 shares of the medical research company’s stock valued at $4,159,000 after buying an additional 474 shares during the period. Huntington National Bank raised its position in Thermo Fisher Scientific by 6.9% in the first quarter. Huntington National Bank now owns 186,907 shares of the medical research company’s stock valued at $28,708,000 after buying an additional 12,025 shares during the period. Finally, Rothschild Investment Corp IL raised its position in Thermo Fisher Scientific by 114.0% in the first quarter. Rothschild Investment Corp IL now owns 70,732 shares of the medical research company’s stock valued at $10,864,000 after buying an additional 37,675 shares during the period. Institutional investors and hedge funds own 87.60% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE TMO) traded up 0.72% during midday trading on Friday, hitting $177.22. The company had a trading volume of 1,537,681 shares. The company’s 50 day moving average is $176.80 and its 200-day moving average is $167.41. The company has a market cap of $69.14 billion, a P/E ratio of 30.87 and a beta of 1.06. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.03 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.

TRADEMARK VIOLATION NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2017/08/27/thermo-fisher-scientific-inc-tmo-position-maintained-by-spf-beheer-bv.html.

Several equities analysts recently commented on the company. Bank of America Corporation reissued a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Barclays PLC reissued an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Wells Fargo & Company reissued an “outperform” rating and set a $200.00 price target (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, BidaskClub raised Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $188.56.

In related news, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total value of $175,200.00. Following the completion of the sale, the director now directly owns 38,757 shares in the company, valued at $6,790,226.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,818 shares of company stock valued at $6,028,985. 0.49% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.